CQDM operates through its representative bodies: the Board of Directors and its committees, officers, members and other representatives.

Board of Directors

Board of Directors

The Board of Directors and its five sub-committees are largely responsible for the governance of the biopharmaceutical research consortium. Members of the Board meet four times per year and oversee the sound management of the biopharmaceutical research consortium. They ensure that financial matters are dealt with carefully and independently, in compliance with the selection criteria of each funding program maintained by CQDM.

Members of the Board of Directors represent all stakeholders of the biopharmaceutical research consortium and draw on their extensive experience to help CQDM maximize the impact of funded projects and reach its objectives.

Chairman

Richard

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

Members

JChan Pic e1720638008209

Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada

Pierre Cote

Pierre Côte
Global Senior Director, Medical, Science, Strategy for Specialty Care
Sanofi États-Unis

Michele DElia

Michele D’Elia
Executive Director – Medical and Scientific Affairs,
Roche Diagnostics

Diane Gosselin

Diane Gosselin
President and Chief Executive Officer,
CQDM

Daniel

Daniel Hétu
Managing Director,
Lumira Ventures

Rafi Hofstein

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Carole Jabet

Carole Jabet
Scientific Director,
Fonds de recherche du Québec

Sarah Jenna Headshot scaled

Sarah Jenna
Director General, 
QV Studio

Steven Klein

Steven Klein
Chief Business Officer,
Epitopea

kpastor photo 1

Ken Pastor
General Partner,
CTI Capital

Louise

Louise Proulx
Corporate Director

Jorge Puente

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

Philip Tagari

Philip Tagari
Chief Scientific Officer,
Insitro

Honorary Member

Rémi Quirion
Chief Scientist of Quebec

Observers

Nathalie Girard
Strategic Projects Coordinator
Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE)

Daria Riabinina
Director of Collaborative Research
Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE)

Secretary

François Painchaud
Lawyer, Partner,
ROBIC, LLP

Other committees

The Executive Committee meets regularly to settle specific aspects of the biopharmaceutical research consortium’s business activities.

Chairman

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

Members

Jennifer Chan
Vice President, Policy and External Affairs,
Merck Canada

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Ken Pastor
General Partner,
CTI Capital

Louise Proulx
Corporate Director

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

The Audit Committee is a sub-committee of the Board that meets at least twice per year to review the financial statements and receive notification of any errors or misstatements contained in financial statements from the external auditors.

Chairman

Ken Pastor
General Partner,
CTI Capital

Members

Richard Fajzel
Chief Executive Officer,
Exactis Innovation

Daniel Hétu
Managing Director,
Lumira Ventures

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

The Corporate Governance and Nominating Committee ensures that the best resources and members are supporting the structure and governance of the biopharmaceutical research consortium. The Committee oversees the recruitment, resignation and replacement process of new Board members. Its ultimate goal is to help CQDM focus on executing its strategy, while leveraging the experience of the Board.

Chairman

Richard Fajzel
Former – President, Chief Executive Officer,
Exactis Innovation

Members

Diane Gosselin
President and Chief Executive Officer,
CQDM

Raphael Hofstein
Former – President and Chief Executive Officer,
Toronto Innovation Acceleration Partners (TIAP)

Jorge Puente
Co-Founder and Managing Partner,
Pleasanton Pharma Ventures

The Scientific Advisory Board was established by the Board of Directors and is composed of experienced, independent scientists. The members review all external scientific evaluations obtained by CQDM, ensure that projects selected for funding meet all criteria, and present their recommendations to the Board of Directors. The Scientific Advisory Board is why CQDM can attest to maintaining a stringent selection process that maximizes positive R&D impacts for its members.

Chairman

Brian Underdown
Biotechnology Consultant,
BJU Consulting

Observers

Diane Gosselin
President and Chief Executive Officer,
CQDM

Catherine Richard
Advisor, Industrial Partnerships,
Quebec Ministry of Economy and Innovation (MEI)

Members

David Bouffard
PMT (Personalize my Treatment) Director,
Exactis Innovation

Cameron Black
Executive Vice President Discovery
Repare Therapeutics

Christine Brideau
Vice President of In Vitro Pharmacology
Deerfield Discovery and Development, LLC

André Darveau
Executive Vice Rector and Vice Rector, Human Resources and Finance
Université Laval

John Delaney
Biotechnology Sr. Advisor

Benjamin Haibe-Kains
Senior Scientist
Princess-Margaret – University Health Network

Jennifer Hamilton
Life sciences consultant

Mark Lim
Vice President | Research, Discovery, and Innovation
ASN Alliance for Kidney Health

Kuldeep Neote
Entrepreneur In Residence
National Institutes of Health & FACIT/OICR